ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

selatogrel

Also written as “Selatogrel”, “ACT-246475” and “Selatogrel 8 mg”.

Its studies are mostly in Myocardial Infarction · Coronary Artery Disease, led by 2 companies.

Drug pageSelatogrel: every studyAll 11 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jun 28, 202111 company-led studies, 1 open or runningNext primary completion: Jul 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Viatris101 open or runningphase 3since Jun 28, 2021Dec 20, 2017Jul 2027phase 3 · NCT04957719
Idorsia Pharmaceuticalsits history only10 open or runningphase 1since Sep 27, 2013Sep 27, 2013none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Viatris only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 20, 2017First study: phase 2 study in Stable Coronary Artery DiseaseFirst studyNCT03384966 · 346 enrolled · United States, Canada, Denmark and more
  2. Jan 30, 2018Phase 1 study in HealthyNCT03430661 · 77 enrolled · United States
  3. Mar 26, 2018Phase 2 study in Acute Myocardial InfarctionNCT03487445 · 48 enrolled · Belgium, Israel, Switzerland
  4. Jun 9, 2018Named selatogrelINNProposed as its International Nonproprietary Name in WHO's List 119 · before, ACT-246475
  5. Jul 10, 2018Phase 1 study in Healthy SubjectsNCT03593278 · 6 enrolled · Germany
  6. Jan 21, 2019Phase 1 study in Healthy SubjectNCT03814200 · 14 enrolled · Netherlands
  7. May 25, 2020Phase 1 study in Healthy SubjectsNCT04406896 · 24 enrolled · Germany
  8. Sep 7, 2020Phase 1 study in Healthy SubjectsNCT04557280 · 24 enrolled · United States
  9. Jun 28, 2021Phase 3 study in Acute Myocardial InfarctionNCT04957719 · 25,000 planned · United States, Australia, Austria and more
  10. Aug 13, 2025Phase 1 study in Healthy VolunteersNCT07133191 · 32 enrolled · United States
  11. May 22, 2026Phase 1 study in Chronic Coronary SyndromeNCT07615868 · 20 enrolled · China

Ahead

  1. Jul 2027Primary completion: phase 3 study in Acute Myocardial InfarctionNCT04957719

TargetBeta

P2RY12 →read by rule
“Purinergic receptor P2Y12 antagonist”ChEMBL 37, by rule

Other programs on P2RY12

ProgramCompanyFurthest phaseStudies
ClopidogrelruleSanofiphase 471
TicagrelorruleAstraZenecaphase 447

Studies

All 10 Viatris leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07615868Chronic Coronary Syndrome · China1CompletedSep 19, 202620
NCT07133191Healthy Volunteers · United States1CompletedNov 5, 202532
NCT04957719Acute Myocardial Infarction · United States, Australia, Austria and more3By invitationJul 202725,000
NCT04557280Healthy Subjects · United States1CompletedDec 19, 202024
NCT04406896Healthy Subjects · Germany1CompletedOct 23, 202024
NCT03814200Healthy Subject · Netherlands1CompletedFeb 12, 201914
NCT03593278Healthy Subjects · Germany1CompletedAug 5, 20186
NCT03487445Acute Myocardial Infarction · Belgium, Israel, Switzerland2CompletedNov 10, 201848
NCT03430661Healthy · United States1CompletedMay 20, 201977
NCT03384966Stable Coronary Artery Disease · United States, Canada, Denmark and more2CompletedAug 18, 2018346

How it is read

Names in the registry

  • “Selatogrel”, 8 entries
  • “ACT-246475”, 3 entries
  • “Selatogrel 8 mg”, 1 entry
  • “Selatogrel 16 mg”, 1 entry
  • “ACT-246475 (Group G dose to be defined)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.